Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: N who wrote (532)	1/22/1998 2:41:00 AM
From: Pseudo Biologist	Read Replies (2) \| Respond to of 1972

Nancy, re. the dna vaccine web site, he may be referring to: genweb.com It was mentioned once or twice before back in post ??? The DynaVax cross-licensing agreement was announced a few weeks back; click on the News "button" at the top of the thread for the details. The issue is that several outside Vical (DynaVax and Apollon among others) have figured out that including some extra DNA sequences (in addition to those specific to the application; e.g., HIV, malaria, etc.) stimulate significantly the kind of immune response one gets. I was getting concerned that Vical was going to be left in the dust without access to this enabling technology. It is now clear that VICL's early lead in the field in general is important enough (we faithful, of course, have known that all along) as to get them access to this new important twist to make the whole thing work. PB